Sherry L Parker

US Patent:

20210252142, Aug 19, 2021

Filed:

Feb 5, 2021

Appl. No.:

17/168554

Inventors:

- Dallas TX, US
Sherry Parker - Dallas TX, US

International Classification:

A61K 39/395
A61K 47/68
A61K 31/573
A61K 9/00
A61K 38/21
A61K 38/17
A61P 31/14
A61P 31/16

Abstract:

The present invention includes composition and methods for treating a patient with a known or suspected viral-induced infection, respiratory disorder or exacerbation thereof, or preventing the same, the method comprising: administering to the patient in need thereof a therapeutically effective amount of an agent, wherein the agent comprises at least one of: (a) an activatable pro-IFN-Fc antibody, (b) an anti-viral-associated antibody or anti-epithelial-associated antibody (aVab/aEab)-IFN-Fc fusion protein, wherein the aVab/aEab is an anti-PD-L1, anti-VEGF, or anti-EGFR antibody variable domain, an activatable pro-aVab/aEab-IFN-Fc, an activatable aVab/aEab-pro-IFN-Fc, or pro-aVab/aEab-pro-IFN-Fc; wherein the fusion antibody prodrugs are activatable by proteases upregulated in upper and lower respiratory tracts during viral infection; wherein the preferred route of administration is via nasopharyngeal or oropharyngeal airways, and wherein the administration results in suppression of viral replication causing a reduction in the viral-induced infection, respiratory disorder or exacerbation thereof in the patient.